CEVEC further strengthens organization to drive industrialization and commercialization of CAP(R) technologies.

CEVEC further strengthens organization to drive industrialization and commercialization of CAP(R) technologies

• Life sciences industry veteran Bart Bergstein to join CEVEC’s Supervisory Board
• Two newly formed Scientific Advisory Boards for CEVEC’s CAP(R)GT and CAP(R)Go technologies will further drive industrialization

Cologne, Germany, June 29^th, 2016 – CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a strengthening of the Company reflective of its strategic progress.

Bart Bergstein, industry veteran and well-known former life sciences venture capitalist, has been appointed to CEVEC’s Supervisory Board, replacing Rainer Christine, who stepped down for personal reasons.

Bart Bergstein brings over 25 years of experience in finance, executive management and investment in innovative life sciences companies to CEVEC’s Advisory Board. Bart’s career includes milestones such as the establishment of the life sciences venture team within ABN AMRO where he and his team built a portfolio of over EUR 100 million in life sciences investments and realizing multiple highly profitable exits. He co-founded Forbion Capital Partners, a Dutch based venture capital firm managing over EUR 500 million in various funds.

High return investments under Bart’s responsibility included Rhein Biotech, Crucell and AM Pharma. Bart also has executive experience as CFO of Cellnovo Group SA where he managed a successful IPO on Euronext Paris. Read more…..